Grifols SA (GIKLY) — SEC Filings
Grifols SA (GIKLY) — 50 SEC filings. Latest: 6-K (Dec 16, 2025). Includes 47 6-K, 2 20-F, 1 SC 13G/A.
Overview
Grifols SA (GIKLY) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Dec 16, 2025: Grifols, S.A. filed a Form 6-K on December 16, 2025, reporting information for the month of December 2025. The filing is from their principal executive office in Sant Cugat del Valles, Barcelona, Spain. Grifols is a foreign private issuer and will file annual reports under Form 20-F.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 4 bullish, 46 neutral. The dominant filing sentiment for Grifols SA is neutral.
Filing Type Overview
Grifols SA (GIKLY) has filed 47 6-K, 2 20-F, 1 SC 13G/A with the SEC between Apr 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of GIKLY's 47 recent filings, 0 were flagged as high-risk, 6 as medium-risk, and 41 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- David I. Bell
Top Tags
foreign-private-issuer (25) · sec-filing (18) · regulatory-filing (14) · 6-k (10) · 6-K (9) · disclosure (8) · reporting (5) · financial-results (3) · revenue-growth (3) · earnings (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenues | EUR 3,677m | Half-Year 2025, up 7.0% at constant currency |
| Net Profit | EUR 177m | Half-Year 2025 |
| Net Revenues | EUR 1,786M | Q1 2025 net revenues increased by 7.4% cc. |
| Adj EBITDA | 14.2% | Adjusted EBITDA increased by 14.2%. |
| Free Cash Flow | EUR 209M | Free cash flow improved by EUR 209 million. |
| Equity Settled Share Based Payment Plan | 457,000,000 | Related to IFRS Restricted Stock Units |
| Pension Defined Benefit Plans | 156,291,1000 | Financial data for 2024 |
| FY24 Revenue | EUR 7,212 million | Exceeded guidance for the full year. |
| FY24 Revenue Growth (cc) | 10.3% | Demonstrates strong top-line performance. |
| Q4 Revenue | EUR 1,976 million | Significant growth driven by Biopharma. |
| Q4 Revenue Growth (cc) | 13.6% | Highlights strong quarterly performance. |
| SEC File Number | 001-35193 | Identifies the specific filing with the SEC. |
| Reporting Period End Date | 2023-12-31 | Fiscal year end for the 20-F filing |
| Prior Year End Date | 2022-12-31 | Comparative period for pension plans |
| Start Date for Pension Plans | 2023-01-01 | Reporting period for defined benefit pension plans |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Grifols SA (GIKLY)?
Grifols SA has 50 recent SEC filings from Apr 2024 to Dec 2025, including 47 6-K, 2 20-F, 1 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of GIKLY filings?
Across 50 filings, the sentiment breakdown is: 4 bullish, 46 neutral. The dominant sentiment is neutral.
Where can I find Grifols SA SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Grifols SA (GIKLY) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Grifols SA?
Financial highlights for Grifols SA are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for GIKLY?
The investment thesis for GIKLY includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Grifols SA?
Key executives identified across Grifols SA's filings include David I. Bell.
What are the main risk factors for Grifols SA stock?
Of GIKLY's 47 assessed filings, 0 were flagged high-risk, 6 medium-risk, and 41 low-risk.
What are recent predictions and forward guidance from Grifols SA?
Forward guidance and predictions for Grifols SA are extracted from SEC filings as they are enriched.